APPLICATIONS PUBLISHED 6 AUGUST 2003
Published: 1-Jan-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Particle formation methods and their products
Nektar Therapeutics UK 1331928*
Transdermal drug delivery system with improved water absorbability and adhesion properties
Samyang Corp 1331929*
Methods and compsns for regulating memory consolidation
Brown University Research Foundation; Howard Hughes Medical Institute 1331930*
Therapeutic use for IP 3? receptor-mediated calcium channel modulators
Contrimmune Biotechnology 1331932*
The use of tiagabine for treatment of diabetic neuropathy and migraine
Abbott Laboratories 1331933*
Activators of peroxisome proliferator-activated alpha and beta receptors as medicaments for treating skin disorders having immunological causes
Phenion 1331934*
Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
Neurim Pharmaceuticals (1991) 1331935*
Mammalian metabolites of a tachykinin receptor antagonist
Merck 1331936*
Dibenzoxazepine alpha V integrin receptor antagonist
Merck 1331937*
Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome
Probi 1331938*
Murraya koenigii extracts for treating asthma
Council of Scientific and Industrial Research 1331939*
Use of a long pentraxin PTX3 for the treatment of diseases caused by an altered activation of the growth factor FGF-2
Sigma-Tau Industrie Farmaceutiche Riunite 1331940*
Organ and biological tissue preservation cold storage solution
Pike Laboratories 1331941*
Immunogen comprising ligand bound HIV envelope protein
Duke University 1331942*
Nucleic acid molecules and polypeptides for immune modulation
Viron Therapeutics 1331943*
Use of CD28-specific monoclonal antibodies for stimulating blood cells that lack CD28
TeGenero 1331944*
Otic microbial combinations for treatment of animals with ruptured tympanic membrane
Bayer Healthcare 1331945*
Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
Schuer, Peter 1331949*
Methods and compsns for nucleic acid delivery
The Johns Hopkins University; Donahue, Kevin J; Marban, Eduardo; Nagata, Koichi; Lawrence, John 1331950*
Orally digestable baked radiophaque
Roff, Roger 1331952*
Indicator systems for determining the effectiveness of a sterilisation procedure
3M Innovative Properties 1331953*
Amidino-urea serotonin receptor ligands and compsns, their pharmaceutical uses, and methods for their synthesis
Warner-Lambert 1332127*
Benzamidine derivatives comprising a sulphate group serving as LTB4 antagonists
Boehringer Ingelheim Pharma 1331128*
Acid derivatives useful as serine protease inhibitors
Bristol-Myers Squibb 1332129*
Atorvastatin hemi-calcium form VII
Teva Pharmaceutical Industries 1332130*
Acid derivatives useful as serine protease inhibitors
Bristol-Myers Squibb 1332131*
Enamine derivatives as cell adhesion molecules
Celltech R&D 1332132*
Metabotropic glutamate receptor antagonists
Janssen Pharmaceutica 1332133*
Inhibitors of prenyl-protease transferase
Merck 1332134*
Pyrimidine-2,4,6-tione metaloproteinase inhibitors
Pfizer Products 1332136*
Treatment of gastrointestinal stromal tumours
Novartis 1332137*
Radiopharmaceuticals for diagnosing Alzheimer's disease
Schering 1332138*
Anticancer agents based on regulation of protein prenylation
The Arizona Disease Control Research Commission 1332139*
Method for the production of menthalactone
Haarman & Reimer 1332140*
Quinazoline derivatives
AstraZeneca 1332141*
Polysubstituted imidazopyiridines as gastric secretion inhibitors
Altana Pharma 1332143*
Indole derivatives as PDE5-inhibitors
Lilly Icos 1332144*
Process for the formulation of antibiotic compounds
Merck 1332145*
Spiro-primidine-2,4,60-trione metalloproteinase inhibitors
Pfizer Products 1332146*
Thieno[2,3-C isoquinolines for use as inhibitors of PARP
SmithKline Beecham 1332147*
Diamino akoxides as polymerisation initiators
Imperial College Innovations 1332148*
Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase
IRB Istituto Di Richerche Biotechnoligiche 1332149*
Modified nucleosides and nucleotides and use thereof
Chattopadhaya, Jyoti 1332150*
Pyranose derivatives
Boehringer Ingelheim Pharma 1332151*
Peptide ligands for prostate specific antigen
Licentia 1332152*
